ID

36454

Description

Dose-Escalation Study of ABBV-838, an Antibody Drug Conjugate, in Subjects With Relapsed and Refractory Multiple Myeloma; ODM derived from: https://clinicaltrials.gov/show/NCT02462525

Lien

https://clinicaltrials.gov/show/NCT02462525

Mots-clés

Versions (1)
  1. 15/05/2019 15/05/2019 -
Détendeur de droits

See clinicaltrials.gov

Téléchargé le

15 mai 2019

DOI

Pour une demande vous connecter.

Licence

Creative Commons BY 4.0
Modèle Commentaires :

Ici, vous pouvez faire des commentaires sur le modèle. À partir des bulles de texte, vous pouvez laisser des commentaires spécifiques sur les groupes Item et les Item.

Retour au modèle Commentaires
Groupe Item commentaires pour :

Item commentaires pour :

Vous devez être connecté pour pouvoir télécharger des formulaires. Veuillez vous connecter ou s’inscrire gratuitement.

Eligibility Multiple Myeloma NCT02462525

Anglais

Eligibility Multiple Myeloma NCT02462525

1 Formulaires  
Inclusion Criteria
Description

Inclusion Criteria

Alias
UMLS CUI
C1512693
eastern cooperative oncology group performance status of 0 to 2
Description

ECOG performance status

Type de données

boolean

Alias
UMLS CUI [1]
C1520224
not eligible for stem cell/bone marrow transplant or have refused stem cell/bone marrow transplant or have relapsed after autologous or allogeneic stem cell/bone marrow transplant
Description

Ineligibility Stem cell transplant | Ineligibility Bone Marrow Transplantation | Stem cell transplant Refused | Bone Marrow Transplantation Refused | Recurrent disease Post Autologous hematopoietic stem cell transplant | Recurrent disease Post Autologous bone marrow transplant | Recurrent disease Post Allogeneic hematopoietic stem cell transplant | Recurrent disease Post Allogeneic bone marrow transplantation

Type de données

boolean

Alias
UMLS CUI [1,1]
C1512714
UMLS CUI [1,2]
C1504389
UMLS CUI [2,1]
C1512714
UMLS CUI [2,2]
C0005961
UMLS CUI [3,1]
C1504389
UMLS CUI [3,2]
C1705116
UMLS CUI [4,1]
C0005961
UMLS CUI [4,2]
C1705116
UMLS CUI [5,1]
C0277556
UMLS CUI [5,2]
C0687676
UMLS CUI [5,3]
C2193200
UMLS CUI [6,1]
C0277556
UMLS CUI [6,2]
C0687676
UMLS CUI [6,3]
C0194037
UMLS CUI [7,1]
C0277556
UMLS CUI [7,2]
C0687676
UMLS CUI [7,3]
C4255274
UMLS CUI [8,1]
C0277556
UMLS CUI [8,2]
C0687676
UMLS CUI [8,3]
C0149615
eligible for and agree to bm aspirate prior to treatment start
Description

Eligibility Bone marrow aspirate

Type de données

boolean

Alias
UMLS CUI [1,1]
C1548635
UMLS CUI [1,2]
C1271729
measurable disease m component in serum (≥ 0.5 g/dl) and/or urine (≥ 0.2 g excreted in a 24 hour collection sample)
Description

Measurable Disease | M Protein Measurement Serum | M Protein Measurement In Urine 24 hour urine sample

Type de données

boolean

Alias
UMLS CUI [1]
C1513041
UMLS CUI [2,1]
C2984963
UMLS CUI [2,2]
C0229671
UMLS CUI [3,1]
C2984963
UMLS CUI [3,2]
C0042037
UMLS CUI [3,3]
C0456209
received at least 2 prior therapies including an imid and a proteasome inhibitor and have demonstrated disease progression on or within 60 days of completion of the last therapy; participants previously treated with an alkylating agent, in addition to an imid or proteasome inhibitor, are allowed to enroll in the trial
Description

Prior Therapy Quantity | Immunomodulators | Proteasome inhibitor | Disease Progression | Alkylating Agents

Type de données

boolean

Alias
UMLS CUI [1,1]
C1514463
UMLS CUI [1,2]
C1265611
UMLS CUI [2]
C1527392
UMLS CUI [3]
C1443643
UMLS CUI [4]
C0242656
UMLS CUI [5]
C0002073
participants must have adequate liver, kidney, and bone morrow function
Description

Liver function | Renal function | Bone Marrow function

Type de données

boolean

Alias
UMLS CUI [1]
C0232741
UMLS CUI [2]
C0232804
UMLS CUI [3,1]
C0005953
UMLS CUI [3,2]
C0031843
participants with a history of chronic heart failure must have cardiac echo indicating left ventricular ejection fraction (lvef) ≥ 45% within 21 days prior to first dose of study drug
Description

Chronic heart failure | Left ventricular ejection fraction Echocardiography

Type de données

boolean

Alias
UMLS CUI [1]
C0264716
UMLS CUI [2,1]
C0428772
UMLS CUI [2,2]
C0013516
Exclusion Criteria
Description

Exclusion Criteria

Alias
UMLS CUI
C0680251
received anti-cancer therapy including chemotherapy, immunotherapy, radiation, biologic, or any investigational therapy within a period of 21 days, herbal therapy within 7 days prior to the first dose of abbv-838, and have unresolved toxicities ≥
Description

Cancer treatment | Chemotherapy | Immunotherapy | Therapeutic radiology procedure | Biological treatment | Therapy, Investigational | Phytotherapy

Type de données

boolean

Alias
UMLS CUI [1]
C0920425
UMLS CUI [2]
C0392920
UMLS CUI [3]
C0021083
UMLS CUI [4]
C1522449
UMLS CUI [5]
C1531518
UMLS CUI [6]
C0949266
UMLS CUI [7]
C0242388
grade 2
Description

Toxicity CTCAE Grades | Resolution Lacking

Type de données

boolean

Alias
UMLS CUI [1,1]
C0600688
UMLS CUI [1,2]
C1516728
UMLS CUI [2,1]
C1514893
UMLS CUI [2,2]
C0332268
concurrent metastatic solid tumors
Description

Solid Neoplasm metastatic

Type de données

boolean

Alias
UMLS CUI [1,1]
C0280100
UMLS CUI [1,2]
C1522484
non-measurable m protein (serum or urine) and measurable sflc (< 100 mg/ml)
Description

M Protein Non-Measurable Serum | M Protein Non-Measurable In Urine | Serum Free Light Chain Measurable

Type de données

boolean

Alias
UMLS CUI [1,1]
C0700271
UMLS CUI [1,2]
C1518373
UMLS CUI [1,3]
C0229671
UMLS CUI [2,1]
C0700271
UMLS CUI [2,2]
C1518373
UMLS CUI [2,3]
C0042037
UMLS CUI [3,1]
C2827352
UMLS CUI [3,2]
C1513040
major surgery within 21 days prior to the first dose of abbv-838
Description

Major surgery

Type de données

boolean

Alias
UMLS CUI [1]
C0679637
clinically significant uncontrolled condition(s) including but not limited to the following:
Description

Condition Clinical Significance Uncontrolled

Type de données

boolean

Alias
UMLS CUI [1,1]
C0348080
UMLS CUI [1,2]
C2826293
UMLS CUI [1,3]
C0205318
grade ≥ 3 peripheral neuropathy or grade 2 peripheral neuropathy with pain uncontrolled hypercalcemia active uncontrolled infection symptomatic congestive heart failure unstable angina pectoris or cardiac arrhythmia psychiatric illness/social situation that would limit compliance with the study
Description

Peripheral Neuropathy CTCAE Grades | Pain | Hypercalcemia Uncontrolled | Communicable Disease Uncontrolled | Symptomatic congestive heart failure | Angina, Unstable | Cardiac Arrhythmia | Mental disorders Limiting Protocol Compliance | Social situation Limiting Protocol Compliance

Type de données

boolean

Alias
UMLS CUI [1,1]
C0031117
UMLS CUI [1,2]
C1516728
UMLS CUI [2]
C0030193
UMLS CUI [3,1]
C0020437
UMLS CUI [3,2]
C0205318
UMLS CUI [4,1]
C0009450
UMLS CUI [4,2]
C0205318
UMLS CUI [5]
C0742758
UMLS CUI [6]
C0002965
UMLS CUI [7]
C0003811
UMLS CUI [8,1]
C0004936
UMLS CUI [8,2]
C0439801
UMLS CUI [8,3]
C0525058
UMLS CUI [9,1]
C0748872
UMLS CUI [9,2]
C0439801
UMLS CUI [9,3]
C0525058
major immunologic reaction to any igg containing agent or auristatin based agent
Description

Immunologic reaction Major Immunoglobulin G | Immunologic reaction Major Auristatin

Type de données

boolean

Alias
UMLS CUI [1,1]
C0301873
UMLS CUI [1,2]
C0205164
UMLS CUI [1,3]
C0020852
UMLS CUI [2,1]
C0301873
UMLS CUI [2,2]
C0205164
UMLS CUI [2,3]
C2742798
participants who are taking strong cyp3a4 inhibitors
Description

CYP3A4 Inhibitors Strong

Type de données

boolean

Alias
UMLS CUI [1,1]
C3850053
UMLS CUI [1,2]
C0442821
Retour au début de la page

Similar models

Eligibility Multiple Myeloma NCT02462525

1 Formulaires
Name
Type
Description | Question | Decode (Coded Value)
Type de données
Alias
Item Group
C1512693 (UMLS CUI)
ECOG performance status
Item
eastern cooperative oncology group performance status of 0 to 2
boolean
C1520224 (UMLS CUI [1])
Ineligibility Stem cell transplant | Ineligibility Bone Marrow Transplantation | Stem cell transplant Refused | Bone Marrow Transplantation Refused | Recurrent disease Post Autologous hematopoietic stem cell transplant | Recurrent disease Post Autologous bone marrow transplant | Recurrent disease Post Allogeneic hematopoietic stem cell transplant | Recurrent disease Post Allogeneic bone marrow transplantation
Item
not eligible for stem cell/bone marrow transplant or have refused stem cell/bone marrow transplant or have relapsed after autologous or allogeneic stem cell/bone marrow transplant
boolean
C1512714 (UMLS CUI [1,1])
C1504389 (UMLS CUI [1,2])
C1512714 (UMLS CUI [2,1])
C0005961 (UMLS CUI [2,2])
C1504389 (UMLS CUI [3,1])
C1705116 (UMLS CUI [3,2])
C0005961 (UMLS CUI [4,1])
C1705116 (UMLS CUI [4,2])
C0277556 (UMLS CUI [5,1])
C0687676 (UMLS CUI [5,2])
C2193200 (UMLS CUI [5,3])
C0277556 (UMLS CUI [6,1])
C0687676 (UMLS CUI [6,2])
C0194037 (UMLS CUI [6,3])
C0277556 (UMLS CUI [7,1])
C0687676 (UMLS CUI [7,2])
C4255274 (UMLS CUI [7,3])
C0277556 (UMLS CUI [8,1])
C0687676 (UMLS CUI [8,2])
C0149615 (UMLS CUI [8,3])
Eligibility Bone marrow aspirate
Item
eligible for and agree to bm aspirate prior to treatment start
boolean
C1548635 (UMLS CUI [1,1])
C1271729 (UMLS CUI [1,2])
Measurable Disease | M Protein Measurement Serum | M Protein Measurement In Urine 24 hour urine sample
Item
measurable disease m component in serum (≥ 0.5 g/dl) and/or urine (≥ 0.2 g excreted in a 24 hour collection sample)
boolean
C1513041 (UMLS CUI [1])
C2984963 (UMLS CUI [2,1])
C0229671 (UMLS CUI [2,2])
C2984963 (UMLS CUI [3,1])
C0042037 (UMLS CUI [3,2])
C0456209 (UMLS CUI [3,3])
Prior Therapy Quantity | Immunomodulators | Proteasome inhibitor | Disease Progression | Alkylating Agents
Item
received at least 2 prior therapies including an imid and a proteasome inhibitor and have demonstrated disease progression on or within 60 days of completion of the last therapy; participants previously treated with an alkylating agent, in addition to an imid or proteasome inhibitor, are allowed to enroll in the trial
boolean
C1514463 (UMLS CUI [1,1])
C1265611 (UMLS CUI [1,2])
C1527392 (UMLS CUI [2])
C1443643 (UMLS CUI [3])
C0242656 (UMLS CUI [4])
C0002073 (UMLS CUI [5])
Liver function | Renal function | Bone Marrow function
Item
participants must have adequate liver, kidney, and bone morrow function
boolean
C0232741 (UMLS CUI [1])
C0232804 (UMLS CUI [2])
C0005953 (UMLS CUI [3,1])
C0031843 (UMLS CUI [3,2])
Chronic heart failure | Left ventricular ejection fraction Echocardiography
Item
participants with a history of chronic heart failure must have cardiac echo indicating left ventricular ejection fraction (lvef) ≥ 45% within 21 days prior to first dose of study drug
boolean
C0264716 (UMLS CUI [1])
C0428772 (UMLS CUI [2,1])
C0013516 (UMLS CUI [2,2])
Item Group
C0680251 (UMLS CUI)
Cancer treatment | Chemotherapy | Immunotherapy | Therapeutic radiology procedure | Biological treatment | Therapy, Investigational | Phytotherapy
Item
received anti-cancer therapy including chemotherapy, immunotherapy, radiation, biologic, or any investigational therapy within a period of 21 days, herbal therapy within 7 days prior to the first dose of abbv-838, and have unresolved toxicities ≥
boolean
C0920425 (UMLS CUI [1])
C0392920 (UMLS CUI [2])
C0021083 (UMLS CUI [3])
C1522449 (UMLS CUI [4])
C1531518 (UMLS CUI [5])
C0949266 (UMLS CUI [6])
C0242388 (UMLS CUI [7])
Toxicity CTCAE Grades | Resolution Lacking
Item
grade 2
boolean
C0600688 (UMLS CUI [1,1])
C1516728 (UMLS CUI [1,2])
C1514893 (UMLS CUI [2,1])
C0332268 (UMLS CUI [2,2])
Solid Neoplasm metastatic
Item
concurrent metastatic solid tumors
boolean
C0280100 (UMLS CUI [1,1])
C1522484 (UMLS CUI [1,2])
M Protein Non-Measurable Serum | M Protein Non-Measurable In Urine | Serum Free Light Chain Measurable
Item
non-measurable m protein (serum or urine) and measurable sflc (< 100 mg/ml)
boolean
C0700271 (UMLS CUI [1,1])
C1518373 (UMLS CUI [1,2])
C0229671 (UMLS CUI [1,3])
C0700271 (UMLS CUI [2,1])
C1518373 (UMLS CUI [2,2])
C0042037 (UMLS CUI [2,3])
C2827352 (UMLS CUI [3,1])
C1513040 (UMLS CUI [3,2])
Major surgery
Item
major surgery within 21 days prior to the first dose of abbv-838
boolean
C0679637 (UMLS CUI [1])
Condition Clinical Significance Uncontrolled
Item
clinically significant uncontrolled condition(s) including but not limited to the following:
boolean
C0348080 (UMLS CUI [1,1])
C2826293 (UMLS CUI [1,2])
C0205318 (UMLS CUI [1,3])
Peripheral Neuropathy CTCAE Grades | Pain | Hypercalcemia Uncontrolled | Communicable Disease Uncontrolled | Symptomatic congestive heart failure | Angina, Unstable | Cardiac Arrhythmia | Mental disorders Limiting Protocol Compliance | Social situation Limiting Protocol Compliance
Item
grade ≥ 3 peripheral neuropathy or grade 2 peripheral neuropathy with pain uncontrolled hypercalcemia active uncontrolled infection symptomatic congestive heart failure unstable angina pectoris or cardiac arrhythmia psychiatric illness/social situation that would limit compliance with the study
boolean
C0031117 (UMLS CUI [1,1])
C1516728 (UMLS CUI [1,2])
C0030193 (UMLS CUI [2])
C0020437 (UMLS CUI [3,1])
C0205318 (UMLS CUI [3,2])
C0009450 (UMLS CUI [4,1])
C0205318 (UMLS CUI [4,2])
C0742758 (UMLS CUI [5])
C0002965 (UMLS CUI [6])
C0003811 (UMLS CUI [7])
C0004936 (UMLS CUI [8,1])
C0439801 (UMLS CUI [8,2])
C0525058 (UMLS CUI [8,3])
C0748872 (UMLS CUI [9,1])
C0439801 (UMLS CUI [9,2])
C0525058 (UMLS CUI [9,3])
Immunologic reaction Major Immunoglobulin G | Immunologic reaction Major Auristatin
Item
major immunologic reaction to any igg containing agent or auristatin based agent
boolean
C0301873 (UMLS CUI [1,1])
C0205164 (UMLS CUI [1,2])
C0020852 (UMLS CUI [1,3])
C0301873 (UMLS CUI [2,1])
C0205164 (UMLS CUI [2,2])
C2742798 (UMLS CUI [2,3])
CYP3A4 Inhibitors Strong
Item
participants who are taking strong cyp3a4 inhibitors
boolean
C3850053 (UMLS CUI [1,1])
C0442821 (UMLS CUI [1,2])
Retour au début de la page 

Contact

Utilisez ce formulaire pour les retours, les questions et les améliorations suggérées.

Les champs marqués d’un * sont obligatoires.

Aide

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial